Identifying disease-modifying potential in myelofibrosis clinical trials

Area of Science:

• Hematologic Malignancy Research
• Clinical Trial Design and Endpoints

Background:

• Overall survival is the primary goal for new hematologic malignancy drugs.
• Surrogate endpoints accelerate outcome assessment but must accurately reflect disease modification.
• Current Janus kinase (JAK) inhibitors for myelofibrosis (MF) improve symptoms but not the disease's natural history.

Purpose of the Study:

• To evaluate the suitability of current clinical trial endpoints for myelofibrosis (MF).
• To propose alternative molecular endpoints for assessing disease modification in MF drug development.
• To accelerate the clinical development of novel agents for MF.

Main Methods:

• Review of established surrogate endpoints in hematologic malignancies.
• Analysis of the impact of JAK inhibitors on MF natural history.
• Proposal for utilizing molecular endpoints, such as mutation burden reduction.

Main Results:

• Established endpoints for MF trials primarily measure symptom burden and splenomegaly, not disease modification.
• JAK inhibitors show limited impact on the natural history of MF despite symptom improvement.
• Current trial endpoints may hinder the development of truly disease-modifying therapies for MF.

Conclusions:

• Rethinking clinical trial endpoints is crucial for advancing MF treatment.
• Molecular endpoints, like reduction in mutation burden, offer a more accurate measure of disease modification.
• Adopting new endpoints will accelerate the development of effective therapies for myelofibrosis.